Tectonic Therapeutic, Inc. (TECX)

Market Cap	699.87M
Revenue (ttm)	n/a
Net Income (ttm)	-53.48M
Shares Out	14.75M
EPS (ttm)	-3.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,940
Open	43.78
Previous Close	44.06
Day's Range	43.28 - 48.47
52-Week Range	1.40 - 53.34
Beta	n/a
Analysts	Strong Buy
Price Target	72.25 (+52.3%)
Earnings Date	Nov 7, 2024

About TECX

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangie...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: TECX
• Website: https://tectonictx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 5 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price forecast is $72.25, which is an increase of 52.30% from the latest price.

Price Target

$72.25

(52.30% upside)

Analyst Consensus: Strong Buy